EODData

MEMBERSHIP REGISTER LOG IN

FRA, 2CL: BridgeBio Pharma, Inc.

05 Nov 2025
LAST:

53.34

CHANGE:
 0.26		OPEN:
52.96		HIGH:
53.34		ASK:
0.00		VOLUME:
200
CHG(%):
0.49		PREV:
53.08		LOW:
52.96		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 2552.9653.3452.9653.34200
04 Nov 2552.8653.0852.8653.08200
31 Oct 2554.5854.8854.4054.40200
30 Oct 2555.4657.4255.4657.422.8K
29 Oct 2557.8857.8855.8655.862.8K
28 Oct 2555.5255.5253.8053.802.8K
27 Oct 2548.3053.3048.0652.822.8K
24 Oct 2546.2246.4446.2246.44280
23 Oct 2545.6645.6645.4045.40280
22 Oct 2546.5246.5246.1546.15280

COMPANY PROFILE

Name:BridgeBio Pharma, Inc.
About:BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Sector:Healthcare
Industry:Biotechnology
Address:3160 Porter Drive, Palo Alto, CA, United States, 94304
Website:https://bridgebio.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-18.43 
Forward P/E:-15.11 
PEG Ratio:-0.13 
Price to Sales:29.47 
Price to Book:-5.69 
Profit Margin:-2.25 
Operating Margin:-1.13 
Return on Assets:-0.43 
Return on Equity:0.37 
Revenue:307.05M 
Shares:191.17M 
Market Cap:10.197B 

TECHNICAL INDICATORS

MA5:54.822.8%
MA10:51.872.8%
MA20:49.537.7%
MA50:45.8516.3%
MA100:42.1426.6%
MA200:36.7445.2%
STO9:63.62
STO14:63.62
RSI14:62.35 
WPR14:-33.94
MTM14:4.73
ROC14:0.10 
ATR:1.97 
Week High:57.888.5%
Week Low:52.860.9%
Month High:57.888.5%
Month Low:44.7945.2%
Year High:57.888.5%
Year Low:20.49160.3%